Drugs / Deupirfenidone
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06717100 | Dec 2024 → Feb 2025 | — | PureTech | Completed | No outcome recorded |
| Phase 1 | NCT07456800 | Jul 2021 → Jan 2022 | — | PureTech | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05321420 | Jul 2022 → Oct 2024 overdue | idiopathic pulmonary fibrosis | PureTech | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04652518 | Dec 2020 → Jun 2022 | COVID-19, post-COVID-19 disorder | PureTech | Terminated | No outcome recorded |
| Phase 2 | NCT04243837 | Mar 2020 → Sep 2022 | lymphedema | PureTech | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07284602 | Jun 2026 → Jun 2029 expected | idiopathic pulmonary fibrosis | PureTech | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Deupirfenidone | “Deupirfenidone (LYT-100) 275 MG” NCT06717100 ↗ |
| Known as | LYT-100 | “LYT-100 (Deupirfenidone) 550 mg TID oral administration” NCT05321420 ↗ |
| Route | Oral | “oral administration” NCT04652518 ↗ |